First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Autio KA, Higano CS, Nordquist L, Appleman LJ, Zhang T, Zhu XH, Babiker H, Vogelzang NJ, Prasad SM, Schweizer MT, Madan RA, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang IM, Zheng J, Tang SY, Hollingsworth R, Kern KA, Petrylak DP.
Autio KA, et al. Among authors: prasad sm.
J Immunother Cancer. 2023 Mar;11(3):e005702. doi: 10.1136/jitc-2022-005702.
J Immunother Cancer. 2023.
PMID: 36948505
Free PMC article.
Clinical Trial.